David Charles Lubner - Net Worth and Insider Trading
David Charles Lubner Net Worth
The estimated net worth of David Charles Lubner is at least $52,621 dollars as of 2024-12-01. David Charles Lubner is the Director of POINT Biopharma Global Inc and owns about 3,600 shares of POINT Biopharma Global Inc (PNT) stock worth over $45,000. David Charles Lubner is also the SVP and CFO of Tetraphase Pharmaceuticals Inc and owns about 3,464 shares of Tetraphase Pharmaceuticals Inc (TTPH) stock worth over $7,621. Details can be seen in David Charles Lubner's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David Charles Lubner has not made any transactions after 2022-11-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of David Charles Lubner
David Charles Lubner Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, David Charles Lubner owns 9 companies in total, including Dyne Therapeutics Inc (DYN) , Therapeutics Acquisition Corp (RACA) , and Ra Pharmaceuticals Inc (RARX) among others .
Click here to see the complete history of David Charles Lubner’s form 4 insider trades.
Insider Ownership Summary of David Charles Lubner
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
DYN | Dyne Therapeutics Inc | 2020-09-16 | director |
RACA | Therapeutics Acquisition Corp | 2020-07-07 | director |
RARX | Ra Pharmaceuticals Inc | 2020-04-02 | Executive VP and CFO |
2019-06-07 | director | ||
2015-08-14 | SVP and CFO | ||
2022-02-03 | director | ||
2022-11-23 | director | ||
2021-10-04 | director | ||
2021-02-04 | director |
David Charles Lubner Latest Holdings Summary
David Charles Lubner currently owns a total of 2 stocks. Among these stocks, David Charles Lubner owns 3,600 shares of POINT Biopharma Global Inc (PNT) as of November 23, 2022, with a value of $45,000 and a weighting of 85.52%. David Charles Lubner also owns 3,464 shares of Tetraphase Pharmaceuticals Inc (TTPH) as of August 14, 2015, with a value of $7,621 and a weighting of 14.48%.
Latest Holdings of David Charles Lubner
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
PNT | POINT Biopharma Global Inc | 2022-11-23 | 3,600 | 12.50 | 45,000 |
TTPH | Tetraphase Pharmaceuticals Inc | 2015-08-14 | 3,464 | 2.20 | 7,621 |
Holding Weightings of David Charles Lubner
David Charles Lubner Form 4 Trading Tracker
According to the SEC Form 4 filings, David Charles Lubner has made a total of 1 transactions in POINT Biopharma Global Inc (PNT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in POINT Biopharma Global Inc is the acquisition of 3,600 shares on November 23, 2022, which cost David Charles Lubner around $24,660.
According to the SEC Form 4 filings, David Charles Lubner has made a total of 0 transactions in Tetraphase Pharmaceuticals Inc (TTPH) over the past 5 years. The most-recent trade in Tetraphase Pharmaceuticals Inc is the sale of 475 shares on August 14, 2015, which brought David Charles Lubner around $407,740.
Insider Trading History of David Charles Lubner
- 1
David Charles Lubner Trading Performance
GuruFocus tracks the stock performance after each of David Charles Lubner's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David Charles Lubner is 8.6%. GuruFocus also compares David Charles Lubner's trading performance to market benchmark return within the same time period. The performance of stocks bought by David Charles Lubner within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how David Charles Lubner's insider trading performs compared to the benchmark.
Performance of David Charles Lubner
David Charles Lubner Ownership Network
David Charles Lubner Owned Company Details
What does Dyne Therapeutics Inc do?
Who are the key executives at Dyne Therapeutics Inc?
David Charles Lubner is the director of Dyne Therapeutics Inc. Other key executives at Dyne Therapeutics Inc include See Remarks Richard William Scalzo , See Remarks Oxana Beskrovnaya , and director & 10 percent owner Dirk Kersten .
Dyne Therapeutics Inc (DYN) Insider Trades Summary
Over the past 18 months, David Charles Lubner made no insider transaction in Dyne Therapeutics Inc (DYN). Other recent insider transactions involving Dyne Therapeutics Inc (DYN) include a net sale of 466,177 shares made by Dirk Kersten , a net sale of 330,251 shares made by Richard William Scalzo , and a net sale of 273,683 shares made by Susanna Gatti High .
In summary, during the past 3 months, insiders sold 517,179 shares of Dyne Therapeutics Inc (DYN) in total and bought 32,000 shares, with a net sale of 485,179 shares. During the past 18 months, 8,028,019 shares of Dyne Therapeutics Inc (DYN) were sold and 1,746,285 shares were bought by its insiders, resulting in a net sale of 6,281,734 shares.
Dyne Therapeutics Inc (DYN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Dyne Therapeutics Inc Insider Transactions
David Charles Lubner Mailing Address
Above is the net worth, insider trading, and ownership report for David Charles Lubner. You might contact David Charles Lubner via mailing address: C/o Tetraphase Pharmaceuticals, Inc., 480 Arsenal Street, Suite 110, Watertown Ma 02472.